Dataset Information

Financial costs and personal consequences of research misconduct resulting in retracted publications.

ABSTRACT: The number of retracted scientific articles has been increasing. Most retractions are associated with research misconduct, entailing financial costs to funding sources and damage to the careers of those committing misconduct. We sought to calculate the magnitude of these effects. Data relating to retracted manuscripts and authors found by the Office of Research Integrity (ORI) to have committed misconduct were reviewed from public databases. Attributable costs of retracted manuscripts, and publication output and funding of researchers found to have committed misconduct were determined. We found that papers retracted due to misconduct accounted for approximately $58 million in direct funding by the NIH between 1992 and 2012, less than 1% of the NIH budget over this period. Each of these articles accounted for a mean of $392,582 in direct costs (SD $423,256). Researchers experienced a median 91.8% decrease in publication output and large declines in funding after censure by the ORI.

SUBMITTER: Stern AM

PROVIDER: S-EPMC4132287 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Financial costs and personal consequences of research misconduct resulting in retracted publications.

Stern Andrew M AM Casadevall Arturo A Steen R Grant RG Fang Ferric C FC

eLife 20140814

The number of retracted scientific articles has been increasing. Most retractions are associated with research misconduct, entailing financial costs to funding sources and damage to the careers of those committing misconduct. We sought to calculate the magnitude of these effects. Data relating to retracted manuscripts and authors found by the Office of Research Integrity (ORI) to have committed misconduct were reviewed from public databases. Attributable costs of retracted manuscripts, and publi ...[more]

PMID: 25124673

Similar Datasets

Project description:BackgroundMeasures to ensure research integrity have been widely discussed due to the social, economic and scientific impact of research integrity. In the past few years, financial support for health research in emerging countries has steadily increased, resulting in a growing number of scientific publications. These achievements, however, have been accompanied by a rise in retracted publications followed by concerns about the quality and reliability of such publications.ObjectiveThis systematic review aimed to investigate the profile of medical and life sciences research retractions from authors affiliated with Brazilian academic institutions. The chronological trend between publication and retraction date, reasons for the retraction, citation of the article after the retraction, study design, and the number of retracted publications by author and affiliation were assessed. Additionally, the quality, availability and accessibility of data regarding retracted papers from the publishers are described.MethodsTwo independent reviewers searched for articles that had been retracted since 2004 via PubMed, Web of Science, Biblioteca Virtual em Saúde (BVS) and Google Scholar databases. Indexed keywords from Medical Subject Headings (MeSH) and Descritores em Ciências da Saúde (DeCS) in Portuguese, English or Spanish were used. Data were also collected from the Retraction Watch website (www.retractionwatch.com). This study was registered with the PROSPERO systematic review database (CRD42017071647).ResultsA final sample of 65 articles was retrieved from 55 different journals with reported impact factors ranging from 0 to 32.86, with a median value of 4.40 and a mean of 4.69. The types of documents found were erratum (1), retracted articles (3), retracted articles with a retraction notice (5), retraction notices with erratum (3), and retraction notices (45). The assessment of the Retraction Watch website added 8 articles that were not identified by the search strategy using the bibliographic databases. The retracted publications covered a wide range of study designs. Experimental studies (40) and literature reviews (15) accounted for 84.6% of the retracted articles. Within the field of health and life sciences, medical science was the field with the largest number of retractions (34), followed by biological sciences (17). Some articles were retracted for at least two distinct reasons (13). Among the retrieved articles, plagiarism was the main reason for retraction (60%). Missing data were found in 57% of the retraction notices, which was a limitation to this review. In addition, 63% of the articles were cited after their retraction.ConclusionPublications are not retracted solely for research misconduct but also for honest error. Nevertheless, considering authors affiliated with Brazilian institutions, this review concluded that most of the retracted health and life sciences publications were retracted due to research misconduct. Because the number of publications is the most valued indicator of scientific productivity for funding and career progression purposes, a systematic effort from the national research councils, funding agencies, universities and scientific journals is needed to avoid an escalating trend of research misconduct. More investigations are needed to comprehend the underlying factors of research misconduct and its increasing manifestation.

Project description:Although research misconduct is responsible for most retractions in health and life sciences from authors affiliated with Brazilian institutions, there are few studies evaluating retraction notices and research misconduct in the country. Understanding the form of research misconduct may share light on the weaknesses and strengths of individual, organizational, and structural factors toward the implementation of a research integrity culture. This review on policies and practices aims to access the available information from research integrity offices and the guidelines from Brazilian funding institutions and universities who were involved in retractions in health and life science publications based on a previously published systematic review. Additionally, we summarize the available guidelines and policies for research integrity in the country. Additionally, we searched publicly available guidelines and offices for research integrity. In total, 15 institutions were analyzed: five funding agencies and 10 universities. Approximately 40% of the funding agencies promoted local research, and 60% promoted national research. Considering national funding agencies, 66% had the commission on research integrity. Approximately 30% of the universities do not have the official office for research integrity or any publicly available guidelines. Most institutions involved in retractions due to some form of research misconduct. Brazilian institutions involved in publication retractions lack instruments to prevent, supervise, and sanction research misconduct. Institutions of the country have insufficiently developed a system to promote and sustain research integrity practices. Nevertheless, there is a positive movement of researchers who are engaged in the investigation of research integrity, policy creation and training. This study emphasizes increased influence of Brazilian scientific collaboration and production globally as well as the impact of retractions in medical sciences. In contrast, it addresses the need for clear research integrity policies to foster high-quality and trustworthy research.

Project description:Nearly 90 % of allegations of biomedical research misconduct in the United States are dismissed by responsible institutions without any faculty assessment or auditable record. Recently, members of the U.S. Congress have complained that the penalties for those against whom findings of research misconduct are made are too light and that too few grant funds associated with research misconduct have been recovered for use by other researchers and taxpayers. Here we discuss the laws that empower federal agencies that can oversee investigations of biomedical research misconduct: the Office of Research Integrity (ORI) and the Office of the Inspector General (OIG), both located within the Department of Health and Human Services (HHS). Research misconduct investigations pertaining to U.S. physical sciences funded through the National Science Foundation (NSF) are overseen by the NSF's OIG. While OIGs may provide some improvement over the ORI in the handling of research misconduct, we have found that a much more serious flaw exists which undermines an ability to conduct performance audits of the effectiveness by which allegations of research misconduct are handled in the United States. Specifically, sufficient data do not need to be retained by U.S. research institutions funded by HHS or NSF to allow effective audit of why allegations of research misconduct are dismissed before being seen by faculty inquiry or investigative committees. U.S. federal Generally Accepted Government Auditing Standards (GAGAS/Yellow Book), if applied to the research misconduct oversight process, would allow a determination of whether the handling of allegations of biomedical research misconduct actually functions adequately, and if not, how it might be improved. In particular, we propose that independent, external peer review under GAGAS audit standards should be instituted without delay in assessing the performance of ORI, or any other similarly tasked federal agency, in handling allegations of research misconduct.

Dataset Information

Financial costs and personal consequences of research misconduct resulting in retracted publications.

Publications

Financial costs and personal consequences of research misconduct resulting in retracted publications.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets